Lead Product(s): Tak-733
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Recursion Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2020
Under the terms of the agreement, Recursion obtains exclusive worldwide rights to develop and commercialize TAK-733.